The company said, “These results were driven by the highest ever quarterly increase in average number of patients of approximately 500 for the quarter, reaching 8,100 average patients in Q3 2025, accelerating the trajectory toward potential blockbuster status for WAKIX in narcolepsy.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HRMY:
- Harmony Biosciences price target lowered to $43 from $50 at UBS
- Harmony Biosciences price target lowered to $36 from $54 at Deutsche Bank
- Harmony Biosciences price target lowered to $35 from $50 at Mizuho
- Harmony Biosciences price target lowered to $55 from $70 at H.C. Wainwright
- Sell Rating for Harmony Biosciences: Setbacks in R&D and Uncertain Pipeline Outlook